- Home
- SES vs HLVX Comparison
SES vs HLVX Comparison
Compare SES & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SES
- HLVX
- Stock Information
- Founded
- SES 2012
- HLVX 2020
- Country
- SES United States
- HLVX United States
- Employees
- SES N/A
- HLVX 90
- Industry
- SES Auto Parts:O.E.M.
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- SES Consumer Discretionary
- HLVX Health Care
- Exchange
- SES Nasdaq
- HLVX Nasdaq
- Market Cap
- SES 110.3M
- HLVX 92.6M
- IPO Year
- SES N/A
- HLVX 2022
- Fundamental
- Price
- SES $0.41
- HLVX $1.86
- Analyst Decision
- SES Sell
- HLVX Hold
- Analyst Count
- SES 2
- HLVX 5
- Target Price
- SES $1.25
- HLVX $2.33
- AVG Volume (30 Days)
- SES 2.3M
- HLVX 317.3K
- Earning Date
- SES 10-31-2024
- HLVX 11-07-2024
- Dividend Yield
- SES N/A
- HLVX N/A
- EPS Growth
- SES N/A
- HLVX N/A
- EPS
- SES N/A
- HLVX N/A
- Revenue
- SES N/A
- HLVX N/A
- Revenue This Year
- SES N/A
- HLVX N/A
- Revenue Next Year
- SES N/A
- HLVX N/A
- P/E Ratio
- SES N/A
- HLVX N/A
- Revenue Growth
- SES N/A
- HLVX N/A
- 52 Week Low
- SES $0.20
- HLVX $1.55
- 52 Week High
- SES $2.12
- HLVX $20.22
- Technical
- Relative Strength Index (RSI)
- SES 50.65
- HLVX 44.78
- Support Level
- SES $0.36
- HLVX $1.95
- Resistance Level
- SES $0.46
- HLVX $1.97
- Average True Range (ATR)
- SES 0.05
- HLVX 0.07
- MACD
- SES 0.01
- HLVX -0.02
- Stochastic Oscillator
- SES 37.71
- HLVX 10.00
About SES SES AI Corporation
SES AI Corp is a pre-commercialization stage company engaged in the development and initial production of high-performance Lithium-Metal (Li-Metal) rechargeable battery technologies for electric vehicles (EVs), urban air mobility (UAM), which encompasses electric vehicle take-off and landing (eVTOL), and other applications. The company is an integrated Li-Metal battery manufacturer with capabilities in material, cell, module, AI-powered safety algorithms, and recycling.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.